CUMBERLAND PHARMACEUTICALS INC - Common Stock, no par value (CPIX)

Historical Holders from Q1 2014 to Q3 2025

Type / Class
Equity / Common Stock, no par value
Symbol
CPIX on Nasdaq
Shares outstanding
14,965,850
Price per share
$3.25
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
3,407,057
Total reported value
$10,629,501
% of total 13F portfolios
0%
Share change
-275,211
Value change
-$866,493
Number of holders
30
Price from insider filings
$3.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CUMBERLAND PHARMACEUTICALS INC - Common Stock, no par value (CPIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KAZIMI A J 41% $24,120,712 5,702,296 A.J. Kazimi 13 Feb 2025
Ikarian Capital, LLC 4.9% $3,091,842 730,932 Ikarian Capital, LLC 31 Mar 2025
INTEGRATED CORE STRATEGIES (US) LLC 4% -30% $1,618,467 -$571,171 598,634 -26% Integrated Core Strategies (US) LLC 30 Sep 2025
As of 30 Sep 2025, CUMBERLAND PHARMACEUTICALS INC - Common Stock, no par value (CPIX) has 30 institutional shareholders filing 13F forms. They hold 3,407,057 shares. of 14,965,850 outstanding shares (23%) .

Top 25 institutional shareholders own 23% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
MILLENNIUM MANAGEMENT LLC 4% 598,634 -23% 0% $1,867,738
Ikarian Capital, LLC 3.7% 555,932 -6.7% 0.39% $1,734,508
RENAISSANCE TECHNOLOGIES LLC 3.4% 515,465 +4.1% 0% $1,608,251
VANGUARD GROUP INC 2.8% 411,786 0% 0% $1,284,773
DIMENSIONAL FUND ADVISORS LP 1.9% 280,869 +11% 0% $876,312
J. Goldman & Co LP 1.4% 208,143 -5.7% 0.02% $649,406
BRIDGEWAY CAPITAL MANAGEMENT, LLC 1.3% 188,355 0% 0.01% $587,668
BOOTHBAY FUND MANAGEMENT, LLC 1.1% 168,132 -6.7% 0.01% $524,572
GEODE CAPITAL MANAGEMENT, LLC 0.68% 101,621 +1.4% 0% $317,101
Bank of New York Mellon Corp 0.48% 72,513 0% 0% $226,240
BlackRock, Inc. 0.35% 52,129 +1.9% 0% $162,643
ACADIAN ASSET MANAGEMENT LLC 0.3% 44,288 0% 0% $138,000
CITADEL ADVISORS LLC 0.28% 41,445 -44% 0% $129,308
TWO SIGMA INVESTMENTS, LP 0.25% 37,591 +17% 0% $117,284
STATE STREET CORP 0.23% 33,700 0% 0% $105,144
Heron Bay Capital Management 0.21% 31,664 -4.8% 0.02% $98,792
NORTHERN TRUST CORP 0.13% 19,603 0% 0% $61,161
Cresset Asset Management, LLC 0.13% 19,475 0% 0% $60,762
XTX Topco Ltd 0.07% 10,591 +3% 0% $33,044
GROUP ONE TRADING LLC 0.05% 7,742 -5.8% 0% $24,155
MORGAN STANLEY 0.02% 3,605 -71% 0% $11,247
UBS Group AG 0.01% 827 -91% 0% $2,580
Tower Research Capital LLC (TRC) 0.01% 787 -63% 0% $2,455
NewEdge Advisors, LLC 0.01% 756 -47% 0% $2,359
JONES FINANCIAL COMPANIES LLLP 0% 600 0% $1,854

Institutional Holders of CUMBERLAND PHARMACEUTICALS INC - Common Stock, no par value (CPIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 3,407,057 $10,629,501 -$866,493 $3.12 30
2025 Q2 3,682,268 $12,334,180 -$2,453,600 $3.35 30
2025 Q1 4,280,014 $18,146,545 +$10,361,901 $4.23 33
2024 Q4 1,842,038 $4,363,682 -$463,906 $2.37 20
2024 Q3 2,043,812 $2,614,244 -$42,880 $1.28 23
2024 Q2 2,077,457 $3,176,639 -$134,140 $1.53 22
2024 Q1 2,162,869 $3,632,852 -$59,437 $1.68 22
2023 Q4 2,197,513 $3,885,597 -$17,578 $1.79 23
2023 Q3 2,207,792 $4,170,727 -$310,715 $1.89 20
2023 Q2 2,399,098 $3,524,781 -$75,732 $1.47 21
2023 Q1 2,447,258 $4,771,188 -$92,986 $1.95 21
2022 Q4 2,493,007 $5,607,314 +$77,997 $2.25 22
2022 Q3 2,428,045 $5,849,000 -$555,953 $2.41 14
2022 Q2 2,708,341 $5,621,000 -$448,503 $2.08 22
2022 Q1 2,874,844 $8,106,000 -$98,930 $2.82 24
2021 Q4 2,835,251 $13,232,000 +$372,626 $4.67 23
2021 Q3 2,767,942 $7,431,000 -$464,461 $2.68 20
2021 Q2 2,939,524 $8,363,000 -$815,456 $2.84 26
2021 Q1 3,205,667 $9,710,000 -$1,946,116 $3.03 28
2020 Q4 3,853,678 $11,358,000 -$516,795 $2.95 23
2020 Q3 4,029,264 $12,934,000 -$360,901 $3.21 22
2020 Q2 4,141,182 $13,791,000 -$1,824,242 $3.33 23
2020 Q1 4,674,157 $16,964,000 +$766,324 $3.63 21
2019 Q4 4,433,367 $22,830,000 -$178,474 $5.15 21
2019 Q3 4,481,799 $26,572,000 -$1,733,901 $5.93 26
2019 Q2 4,768,946 $30,376,000 -$985,062 $6.37 22
2019 Q1 4,924,596 $28,610,000 -$352,511 $5.81 22
2018 Q4 4,984,289 $30,483,000 -$2,112,017 $6.03 22
2018 Q3 5,351,717 $30,556,000 -$41,824 $5.71 29
2018 Q2 5,365,571 $32,884,000 -$465,697 $6.13 29
2018 Q1 5,425,411 $36,242,000 -$49,471 $6.68 29
2017 Q4 5,430,722 $40,086,000 +$361,683 $7.36 31
2017 Q3 89 $1,000 -$535,000 $11.24 1
2017 Q2 5,449,601 $38,275,000 -$395,022 $7.00 33
2017 Q1 5,505,762 $38,201,000 +$3,113,154 $6.94 34
2016 Q4 5,478,126 $30,127,000 +$352,689 $5.50 36
2016 Q3 5,416,164 $27,128,000 +$890,973 $5.00 39
2016 Q2 5,239,489 $23,613,000 +$115,756 $4.50 40
2016 Q1 5,215,045 $23,413,000 -$94,016 $4.49 46
2015 Q4 5,127,642 $26,974,000 -$445,962 $5.26 43
2015 Q3 5,151,887 $29,724,000 +$57,904 $5.77 43
2015 Q2 5,182,281 $37,051,000 -$1,804,311 $7.15 42
2015 Q1 5,449,928 $36,248,000 -$1,525,525 $6.66 41
2014 Q4 5,716,701 $34,220,000 -$3,789,449 $5.98 42
2014 Q3 6,357,061 $31,401,000 -$1,425,250 $4.94 44
2014 Q2 6,670,341 $30,015,297 -$215,534 $4.50 44
2014 Q1 6,719,046 $30,230,294 +$106,519 $4.50 46